Results For:

About Us

About Us Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing targeted natural killer (NK) cell therapies which are supported by Companion Diagnostics. Alphageneron’s team is comprised of

AP-401™ iPSC-Derived Bi-Specific CAR NK Cells

AP-401™ is a novel Induced Pluripotent Stem Cell (iPSC) Bi-Specific CAR NK cell targeting CD155 and CD73 which has shown promising efficacy to solid tumors in animal studies. CD155, one

Investors

Latest News

Latest News: Sharing Our Progress & Industry Developments Edit Date Post March 2023 Our CSO, Graham Pockley, PhD is presenting at the 8th Annual Innate Killer Summit in San Diego,

Pipeline

AP-301™ Immune Cell Engager

AP-301™ Immune Cell Engager AP-301™: Immune Cell Engagers are multi-specific targeted antibodies derived from our unique monoclonal antibodies which recognize membrane Hsp70 antibody. A linker facilitates binding to multiple antigens.